IL-6/STAT3 Pathway Induced Deficiency of RFX1 Contributes to Th17-dependent Autoimmune Diseases Via Epigenetic Regulation.

Ming Zhao,Yixin Tan,Qiao Peng,Cancan Huang,Yu Guo,Gongping Liang,Bochen Zhu,Yi Huang,Aiyun Liu,Zijun Wang,Mengying Li,Xiaofei Gao,Ruifang Wu,Haijing Wu,Hai Long,Qianjin Lu
DOI: https://doi.org/10.1038/s41467-018-02890-0
IF: 16.6
2018-01-01
Nature Communications
Abstract:Epigenetic modifications affect the differentiation of T cell subsets and the pathogenesis of autoimmune diseases, but many mechanisms of epigenetic regulation of T cell differentiation are unclear. Here we show reduced expression of the transcription factor RFX1 in CD4(+) T cells from patients with systemic lupus erythematosus, which leads to IL-17A overexpression through increased histone H3 acetylation and decreased DNA methylation and H3K9 tri-methylation. Conditional deletion of Rfx1 in mice exacerbates experimental autoimmune encephalomyelitis and pristane-induced lupus-like syndrome and increases induction of Th17 cells. In vitro, Rfx1 deficiency increases the differentiation of naive CD4(+) T cells into Th17 cells, but this effect can be reversed by forced expression of Rfx1. Importantly, RFX1 functions downstream of STAT3 and phosphorylated STAT3 can inhibit RFX1 expression, highlighting a non-canonical pathway that regulates differentiation of Th17 cells. Collectively, our findings identify a unique role for RFX1 in Th17-related autoimmune diseases.
What problem does this paper attempt to address?